Vapaliximab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | VAP-1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII | |
NY (what is this?) |
Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug.[citation needed] Development was discontinued by 2012.[2]
References[]
- ^ WHO Drug Information
- ^ "Vapaliximab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.
show
| |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (initiation) |
| ||||||||||||||
Intracellular (reception) |
| ||||||||||||||
Extracellular |
|
This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
- v
- t
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
Hidden categories:
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- All articles with unsourced statements
- Articles with unsourced statements from October 2009
- All stub articles